Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 7Leukemia, Myeloid, Acute 5Recurrence 4Hepatitis C, Chronic 4Hepatitis C 4Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Respiratory Tract Infections 2Lymphoma, Mantle-Cell 2Infections 2Head and Neck Neoplasms 2Breast Neoplasms 2Wilms Tumor 1Testicular Neoplasms 1Teratoma, Testicular 1Teratoma 1Seminoma 1Respiratory Syncytial Virus Infections 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Neuroblastoma 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Multiple Myeloma 1Malignant Solid Tumor 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

pembrolizumab 3Ramucirumab 2Nivolumab 2etirinotecan pegol 1cemiplimab 1Ribavirin 1Paclitaxel 1Injections 1Fluorouracil 1Docetaxel 1Decitabine 1Cisplatin 1Carboplatin 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Malignant Solid Tumor × Ribavirin × Clear all
NCT01309490 2025-07-29

Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients

Jewish General Hospital

Phase 1/2 Terminated
5 enrolled
Other solid neoplasm

Malignant Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡